| scholarly article | Q13442814 |
| P50 | author | Margaret E. Ackerman | Q57012155 |
| Chris Bailey-Kellogg | Q89469549 | ||
| P2093 | author name string | Michael S Seaman | |
| Susan Zolla-Pazner | |||
| Karl E Griswold | |||
| Susan K Eszterhas | |||
| Seth A Brooks | |||
| Jennifer I Lai | |||
| Chengzi Guo | |||
| P2860 | cites work | A Blueprint for HIV Vaccine Discovery | Q26829865 |
| Antibodies in HIV-1 vaccine development and therapy | Q27011574 | ||
| Structure and Dynamics of the Native HIV-1 Env Trimer | Q27027570 | ||
| Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 | Q27644478 | ||
| Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2 | Q27675879 | ||
| Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals | Q27677941 | ||
| Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16 | Q27678312 | ||
| Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer | Q27680496 | ||
| Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIV | Q27681527 | ||
| Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design | Q28075274 | ||
| A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies | Q28299280 | ||
| High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples | Q28389941 | ||
| Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein | Q29306052 | ||
| Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand | Q29547531 | ||
| Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation | Q29615068 | ||
| Immune-correlates analysis of an HIV-1 vaccine efficacy trial | Q29617377 | ||
| HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites | Q29619017 | ||
| Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 | Q29619511 | ||
| The V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel | Q30152923 | ||
| V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. | Q33874253 | ||
| HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities | Q33900395 | ||
| Elicitation of HIV-1-neutralizing antibodies against the CD4-binding site. | Q34133551 | ||
| Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice | Q34180174 | ||
| Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1 | Q34292765 | ||
| Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2 | Q34298408 | ||
| Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. | Q34434854 | ||
| Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2. | Q34907398 | ||
| DQB1*0602 rather than DRB1*1501 confers susceptibility to multiple sclerosis-like disease induced by proteolipid protein (PLP). | Q35935131 | ||
| Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials | Q36083337 | ||
| The development of CD4 binding site antibodies during HIV-1 infection | Q36155396 | ||
| Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies | Q36262823 | ||
| Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family | Q36363231 | ||
| Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo | Q36414891 | ||
| Challenges for structure-based HIV vaccine design | Q37667763 | ||
| HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis | Q38357177 | ||
| Fragments of the V1/V2 domain of HIV-1 glycoprotein 120 engineered for improved binding to the broadly neutralizing PG9 antibody | Q38756259 | ||
| Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope | Q38962226 | ||
| Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex | Q39593524 | ||
| Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity. | Q41924059 | ||
| HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees | Q47547483 | ||
| Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated SHIV challenges. | Q51743315 | ||
| Towards conformational fidelity of a quaternary HIV-1 epitope: computational design and directed evolution of a minimal V1V2 antigen. | Q55518743 | ||
| V2-Directed Vaccine-like Antibodies from HIV-1 Infection Identify an Additional K169-Binding Light Chain Motif with Broad ADCC Activity | Q60959639 | ||
| Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers | Q64228820 | ||
| Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort. | Q64967037 | ||
| Removal of endotoxin from protein solutions by phase separation using Triton X-114 | Q68480102 | ||
| Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins | Q80966875 | ||
| Anti-V2 antibody deficiency in individuals infected with HIV-1 in Cameroon | Q91144554 | ||
| Correction: Trinh, H.V., et al. Humoral Response to the HIV-1 Envelope V2 Region in a Thai Early Acute Infection Cohort. Cells 2019, 8, 365 | Q92590076 | ||
| Conformational Plasticity in the HIV-1 Fusion Peptide Facilitates Recognition by Broadly Neutralizing Antibodies | Q92719597 | ||
| P433 | issue | 18 | |
| P1104 | number of pages | 11 | |
| P304 | page(s) | 3436-3446 | |
| P577 | publication date | 2020-03-17 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticity | |
| P478 | volume | 38 |
Search more.